The United States Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) to Aurobindo Pharma’s wholly owned subsidiary -- APL Healthcare’s Unit IV, a Formulation manufacturing facility situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh. The said facility has been classified as Voluntary Action Indicated (VAI).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
